Journal Article

DKFZ-2024-00714

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The fentanyl-specific antibody FenAb024 can shield against carfentanil effects.

Urban, K. ; Gkeka, A. ; Chandra, M. ; Greiner, D. ; Pollich, S. ; Ruf, S.DKFZ* ; Kelemen, Y. ; Sundermann, T. ; Pravetoni, M. ; Baehr, C. ; Stebbins, C. E.DKFZ* ; Papavasiliou, F. N.DKFZ* ; Verdi, J. P. (Last author)DKFZ*

2024
Elsevier Science Amsterdam [u.a.]

This record in other databases:

Please use a persistent id in citations: doi:10.1016/j.toxlet.2024.03.008

Abstract: The surge in opioid-related deaths, driven predominantly by fentanyl and its synthetic derivatives, has become a critical public health concern, which is particularly evident in the United States. While the situation is less severe in Europe, the European Monitoring Centre for Drugs and Drug Addiction reports a rise in drug overdose deaths, with emerging concerns about the impact of fentanyl-related molecules. Synthetic opioids, initially designed for medical use, have infiltrated illicit markets due to their low production costs and high potency, with carfentanil posing additional threats, including potential chemical weaponization. Existing overdose mitigation heavily relies on naloxone, requiring timely intervention and caregiver presence, while therapeutic prevention strategies face many access challenges. To provide an additional treatment option, we propose the use of a fentanyl-specific monoclonal antibody (mAb), as a non-opioid method of prophylaxis against fentanyl and carfentanil. This mAb shows protection from opioid effects in a pre-clinical murine model. mAbs could emerge as a versatile countermeasure in civilian and biodefense settings, offering a novel approach to combat opioid-associated mortality.

Keyword(s): Opioid crisis ; antibody-associated protection ; carfentanil ; fentanyl ; monoclonal antibodies ; passive immunization

Note: #LA:D150# / Volume 396, 15 May 2024, Pages 1-10

---

Contributing Institute(s):

1. D150 Immundiversität (D150)
2. Strukturbiologie von Infektion und Immunität (D160)

Research Program(s):

1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2024

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---